Patents by Inventor Eric Adriaenssens

Eric Adriaenssens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MET receptor agonist proteins
    Patent number: 10435450
    Abstract: Disclosed are proteins derived from the HGF/SF which are able to induce activation of the tyrosine kinase receptor MET and their uses, in particular to promote tissue regeneration. Further disclosed are nucleic acid molecules coding such protein, expression vectors containing such nucleic acid molecule, host cells containing such expression vectors, and related compositions.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: October 8, 2019
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT PASTEUR DE LILLE, UNIVERSITA' DEGLI STUDI DI PAVIA, UNIVERSITÉ DE LILLE
    Inventors: Jerome Vicogne, Oleg Melnyk, Nathalie Ollivier, Eric Adriaenssens, Berenice Leclercq, Claire Simonneau, Giovanni De Nola, Ermanno Gherardi, Hugo De Jonge
  • MULTIMERIC COMPOUNDS OF A KRINGLE DOMAIN FROM THE HEPATOCYTE GROWTH FACTOR / SCATTER FACTOR (HGF/SF)
    Publication number: 20180008723
    Abstract: Disclosed are multimeric compounds of K1 domains from the Hepatocyte Growth Factor/Scatter Factor (HGF/SF) being able to induce activation of the tyrosine kinase receptor MET and their uses.
    Type: Application
    Filed: January 21, 2016
    Publication date: January 11, 2018
    Inventors: Jerome VICOGNE, Oleg MELNYK, Nathalie OLLIVIER, Eric ADRIAENSSENS, Berenice LECLERCQ, Claire SIMONNEAU, Giovanni DE NOLA, Ermanno GHERARDI, Hugo DE JONGE
  • MET RECEPTOR AGONIST PROTEINS
    Publication number: 20170369545
    Abstract: Disclosed are proteins derived from the HGF/SF which are able to induce activation of the tyrosine kinase receptor MET and their uses, in particular to promote tissue regeneration. Further disclosed are nucleic acid molecules coding such protein, expression vectors containing such nucleic acid molecule, host cells containing such expression vectors, and related compositions.
    Type: Application
    Filed: January 21, 2016
    Publication date: December 28, 2017
    Inventors: Jerome VICOGNE, Oleg MELNYK, Nathalie OLLIVIER, Eric ADRIAENSSENS, Berenice LECLERCQ, Claire SIMONNEAU, Giovanni DE NOLA, Ermanno GHERARDI, Hugo DE JONGE
  • Method for NGF assay for in vitro diagnosis of breast cancer and therapeutic use
    Patent number: 7618790
    Abstract: The present invention concerns a method for the in vitro diagnosis of breast cancer which consists in determining the presence of NGF in a biological sample derived from a patient suspected of suffering from breast cancer. Said method may be used both in early diagnosis, screening, therapeutic follow-up and prognosis, and in the diagnosis of relapse in the case of breast cancer. The present invention also concerns the use of an NGF binding partner or of an NGF inhibitor for preparing a medicinal product, said medicinal product being in particular useful for blocking tumor proliferation and remote dissemination in patients suffering from breast cancer.
    Type: Grant
    Filed: October 28, 2003
    Date of Patent: November 17, 2009
    Assignees: Biomerieux, Universite des Sciences et Technologies de Lille
    Inventors: Eric Adriaenssens, Geneviéve Choquet-Kastylevsky, Laurent Dolle, Ikram El-Yazidi Belkoura, Hubert Hondermarck
  • Method for ngf assay for in vitro diagnosis of breast cancer and therapeutic use
    Publication number: 20060051818
    Abstract: The present invention concerns a method for the in vitro diagnosis of breast cancer which consists in determining the presence of NGF in a biological sample derived from a patient suspected of suffering from breast cancer. Said method may be used both in early diagnosis, screening, therapeutic follow-up and prognosis, and in the diagnosis of relapse in the case of breast cancer. The present invention also concerns the use of an NGF binding partner or of an NGF inhibitor for preparing a medicinal product, said medicinal product being in particular useful for blocking tumor proliferation and remote dissemination in patients suffering from breast cancer.
    Type: Application
    Filed: October 28, 2003
    Publication date: March 9, 2006
    Applicants: Biomerieux, Universite' Des Sciences Et Technologies De Lille
    Inventors: Eric Adriaenssens, Genevieve Choquet-Kastylevsky, Laurent Dolle, Ikram El-Yazidi Belkoura, Hubert Hondermarck